ISRCTN51295799
Completed
Phase 2
An investigation of the efficacy of a single dose of insulin in the prevention of excessive cutaneous scarring in breast surgery patients: a phase II randomised controlled clinical trial
Pharmecosse Ltd (UK)0 sites75 target enrollmentAugust 26, 2010
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Pharmecosse Ltd (UK)
- Enrollment
- 75
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
2018 results in https://www.ncbi.nlm.nih.gov/m/pubmed/29240641/ (added 17/01/2019)
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Female patients aged 18 \- 60 years
- •2\. Undergoing non\-cancer related bilateral breast surgery \- this patient group has been chosen for two reasons: Firstly they have two identical wounds allowing an ideal intra\-patient placebo control since scarring severity varies markedly not only between individuals but also between body sites. Secondly these wounds have a high tendency towards formation of excessive scarring.
Exclusion Criteria
- •1\. Patients with diagnosed breast cancer
- •2\. Patients with a history (either individual or familial) of keloid scarring (suspected to have a genetic component). Keloid scars are the most severe and pernicious form of pathological scarring that unlike hypertrophic scarring appear to behave in an almost cancer\-like fashion invading the surrounding non\-wounded normal tissue. The causes of this form of scarring are likely to be more complex and potentially multi\-factorial. In addition this particular condition is thought to have a genetic link and might therefore introduce extra variables which might complicate correct analysis of results.
- •3\. Younger than 18 or older than 60 (The rate of wound healing is known to be different within these two age groups)
- •4\. Smokers \- impairs wound healing
- •5\. Any systemic illness that could have a theoretical interaction with the insulin administered such as diabetics, patients with renal or liver disease or endocrine tumours
- •Exclusion criteria 2 \- 4 are designed to eliminate extra variables which might complicate correct analysis of results. These criteria are largely theoretical as patients who do exhibit any of these features are unlikely to be put forward for non\-cancer related breast surgery.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
niversal warming protocolWarming cryopreserved human oocytesPregnancy and ChildbirthISRCTN12342851GynePro Medical169
Completed
Not Applicable
A study investigating the effect over 12 weeks of the novel herbal composition SR2004 on haemoglobin A1c, fasting blood glucose and lipids in type 2 diabetic patientsType 2 diabetes mellitusNutritional, Metabolic, EndocrineISRCTN12562776Maccabi Healthcare Services119
Completed
Not Applicable
Efficacy of patient-controlled paravertebral block for single intercostal video assisted thoracic surgeryPain in the postoperative periodSigns and SymptomsISRCTN24097424Second Affiliated Hospital of Zhejiang University260
Completed
Not Applicable
Study comparing single-incision laparoscopy versus multitrocar laparoscopy totally extraperitoneal inguinal hernia repair (TEP) at 2 yearsnilateral or bilateral inguinal hernia requiring surgical treatmentInjury, Occupational Diseases, PoisoningUnilateral or bilateral inguinal herniaISRCTN63754528Saint-Pierre University Hospital210
Completed
Phase 1
Efficacy and safety of olaparib in relapsed and refractory chronic lymphocytic leukaemia patients with an 11q deletion or ATM mutation and relapsed/refractory patients with T-prolymphocytic leukaemia and mantle cell lymphomaChronic lymphocytic leukaemiaCancerLymphoid leukaemiaISRCTN34386131niversity of Birmingham (UK)15